Summary
Amgen Inc. (AMGN) presented its 2022 annual report, highlighting robust product sales growth, particularly driven by Prolia, Repatha, and EVENITY. The company's total product sales increased by 2% to $24.8 billion, despite challenges like biosimilar competition and pricing pressures. A significant strategic move during the year was the announcement of the proposed acquisition of Horizon Therapeutics for approximately $27.8 billion, signaling Amgen's intent to expand its portfolio into rare, autoimmune, and inflammatory diseases. The company also advanced its pipeline, initiating Phase 3 trials for several key programs, including LUMAKRAS/LUMYKRAS for colorectal cancer and olpasiran for cardiovascular disease. Amgen continues to focus on innovation, manufacturing advancements, and global expansion, while navigating a complex regulatory and reimbursement landscape. The company maintained a strong financial position, with significant cash flow from operations and ongoing capital returns to shareholders through dividends and stock repurchases, though it also faces ongoing litigation regarding tax matters with the IRS.
Financial Highlights
56 data points| Revenue | $26.32B |
| Cost of Revenue | $6.41B |
| Gross Profit | $19.92B |
| SG&A Expenses | $5.41B |
| Operating Expenses | $16.76B |
| Operating Income | $9.57B |
| Interest Expense | $1.41B |
| Net Income | $6.55B |
| EPS (Basic) | $12.18 |
| EPS (Diluted) | $12.11 |
| Shares Outstanding (Basic) | 538.00M |
| Shares Outstanding (Diluted) | 541.00M |
Key Highlights
- 1Amgen announced a proposed $27.8 billion acquisition of Horizon Therapeutics to expand its presence in rare and autoimmune diseases.
- 2Total product sales grew 2% to $24.8 billion, driven by volume increases in key products like Prolia, Repatha, and EVENITY.
- 3The company initiated Phase 3 clinical trials for several pipeline candidates, including LUMAKRAS/LUMYKRAS (colorectal cancer) and olpasiran (cardiovascular disease).
- 4Amgen acquired ChemoCentryx for approximately $3.8 billion, adding TAVNEOS to its inflammation portfolio.
- 5Despite biosimilar competition impacting products like Neulasta (sales down 35%), Amgen is also advancing its own biosimilar portfolio.
- 6The company continues to invest heavily in R&D, with expenses totaling $4.4 billion, supporting a pipeline with 18 Phase 3 programs.
- 7Amgen returned significant capital to shareholders in 2022, repurchasing $6.3 billion in stock and increasing its quarterly dividend by 10%.